Fundz
Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly. See plans and pricing.See plans →

Solstice Oncology has launched with a $225 million Series A financing led by RA Capital Management. The funding aims to advance its neoadjuvant immuno-oncology therapy, porustobart, for treating colon cancer.

PRIVATESep 09, 2026•about 4 hours ago

Amount Raised

$225 Million

Round Type

Series A

New YorkBiotechnologyHealth CareArtificial Intelligence

Investors

ForbionCanaan PartnersRa Capital Management

Description

Solstice Oncology, a clinical-stage immuno-oncology company, announced its launch and $225 million Series A financing. The financing will be used to advance porustobart, a second-generation Fc-enhanced CTLA-4 antibody, across clinical indications. The company plans to begin a Phase 2 trial for treating MSS clinical stage II-III colon cancer in the neoadjuvant setting. This approach targets cancer early, potentially benefiting a large segment of colon cancer patients.

Company Information

Company

Solstice Health

Location

New York, New York, United States

About

Solstice is an AI engine for life sciences marketing teams that accelerates the evaluation, creation, and distribution of personalized content. We create the guardrails to streamline compliance review processes.

Don't miss Solstice Health's next move

Get an email the moment Solstice Health raises, hires an exec, or expands, usually minutes after it happens.

One email per event. Unsubscribe anytime.

Related People

Suggested for you
1 contact
Predictive Intelligence
Strategic

ML-powered predictions for Solstice Health's next move

See what Strategic adds

Funding Insights

Based on industry data
Typical timeline to Series B
Series A companies typically raise their next round in 10-18 months
Monthly burn rate benchmark
47% of Series A startups spend $400k or more per month on operations
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Solstice Health raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 285,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.